https://www.fiercebiotech.com/biotech/biontech-pays-autolus-250m-manufacturing-car-t-expertise-wide-ranging-collab
$250 million upfront collaboration.
https://investors.biontech.de/news-releases/news-release-details/biontech-presents-positive-preliminary-phase-12-data-first-class
https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html#bnt211-solid-tumors
BNT211 aimed at solid tumors. They've completed phase 1/2 and looking promising for testicular cancer.
Pharma companies sitting on $171 billion of cash reserves, oncology tipped to be a major focus.
Our Phase 1b and early CHM 2101 data towards the end of the year should put us right in the firing line. Something to keep in mind when people keep taking about our cash reserves.
Can't hurt Chimeric having a world class team of cell therapy pioneers when pharma are doing their assessments
- Forums
- ASX - By Stock
- biotech could be sector for 2024
https://www.fiercebiotech.com/biotech/biontech-pays-autolus-250m-...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
1.7¢ |
Change
0.001(6.25%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
1.7¢ | 1.9¢ | 1.7¢ | $45.06K | 2.512M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 62187 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 200000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 62187 | 0.017 |
17 | 2833886 | 0.016 |
19 | 2586784 | 0.015 |
3 | 708475 | 0.014 |
2 | 222223 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 200000 | 1 |
0.019 | 1896071 | 5 |
0.020 | 1523093 | 7 |
0.021 | 290857 | 3 |
0.022 | 600000 | 2 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online